<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Staging and prognosis of chronic lymphocytic leukemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Staging and prognosis of chronic lymphocytic leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Staging and prognosis of chronic lymphocytic leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kanti R Rai, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Stilgenbauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm) characterized by the progressive accumulation of functionally incompetent lymphocytes, which are usually monoclonal in origin.</p><p>CLL is considered to be identical (ie, one disease with different manifestations) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL), a clinically indolent non-Hodgkin lymphoma. The term CLL is used when the disease manifests primarily in the blood, whereas the term SLL is used when involvement is primarily nodal.</p><p>The staging and prognosis of CLL/SLL will be reviewed here. The pathobiology, clinical manifestations, diagnosis, and treatment of CLL/SLL are discussed separately, as is the related condition monoclonal B cell lymphocytosis.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4539.html" rel="external">"Pathobiology of chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/118011.html" rel="external">"Monoclonal B cell lymphocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>The natural history of CLL/SLL is extremely variable, with survival times from initial diagnosis that range from approximately 2 to 20 years, and a median survival of approximately 10 years [<a href="#rid1">1,2</a>].</p><p>Some patients experience a rapid deterioration and die within two to three years from complications or causes directly related to CLL/SLL. Others follow a clinically benign course for 5 to 10 years, followed by a terminal phase lasting one to two years. A minority of patients (&lt;30 percent) follow a clinically benign course for 10 to 20 years, and the eventual cause of death may be unrelated to CLL/SLL. Spontaneous clinical regression has been reported in the absence of therapy, but it is rare [<a href="#rid3">3</a>].</p><p>During the initial asymptomatic phase, patients maintain their usual lifestyles, but during the terminal phase the performance status can be poor, with recurring need for hospitalization. The most frequent causes of death are severe systemic infection (especially pneumonia and septicemia), bleeding, and inanition with cachexia. During this terminal phase there can be considerable morbidity, both from the disease itself and from complications of therapy. (See  <a class="medical medical_review" href="/z/d/html/4504.html" rel="external">"Overview of the complications of chronic lymphocytic leukemia"</a>.) </p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL STAGING</span></p><p class="headingAnchor" id="H2823676468"><span class="h2">Prognostic value</span><span class="headingEndMark"> — </span>The Rai and Binet staging systems use physical examination and complete blood count to stratify patients into three risk groups (low, intermediate, and high) with different predicted overall survival (OS)  (<a class="graphic graphic_table graphicRef56284" href="/z/d/graphic/56284.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef80421" href="/z/d/graphic/80421.html" rel="external">table 2</a>) and to identify patients who would benefit from treatment (eg, Rai stage III or IV, Binet stage C). </p><p>Survival curves for Rai low risk (stage 0), intermediate risk (stage I or II), and high risk (stage III or IV) groups correspond to those of the Binet stage A, B, and C, respectively. While increasing stage is associated with shorter survival, the absolute survival estimates reported in the original publications are significantly shorter than expected survival with modern therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage reflects burden of disease</strong> – Increasing stage reflects a gradual and progressive increase in the body burden of leukemic lymphocytes, starting in the blood and bone marrow (lymphocytosis), progressively involving lymph nodes (lymphadenopathy), spleen and liver (organomegaly), with eventual compromise of bone marrow function (anemia and thrombocytopenia). </p><p></p><p class="bulletIndent1">With the passage of time, patients tend to progress from an early stage (low risk), to an intermediate stage, and eventually into an advanced stage (high risk) [<a href="#rid1">1</a>]. However, if a patient's stage shifts from a higher risk to a lower risk category with successful therapy, the outlook for survival improves accordingly [<a href="#rid4">4</a>]. These systems were developed with data from patients treated 40 to 50 years ago. Therapy in CLL has markedly improved during the past decades. As such, the prognosis for each stage has improved with the advent of new therapies [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging for selected patients</strong> – Imaging is not used for routine staging, but it should be performed in patients with signs or symptoms concerning for enlarged abdominal or pelvic nodes (eg, obstructive jaundice or obstruction of the inferior vena cava or ureters). (See  <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia", section on 'Indications for treatment ("active disease")'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of autoimmune cytopenias</strong> – While there may be other causes of low blood counts (eg, autoimmune cytopenias, prior therapy, coexisting illness), these are not accounted for when determining stage. However, patients with cytopenias due to autoimmune processes appear to have a better prognosis than patients with cytopenias due to bone marrow failure [<a href="#rid6">6,7</a>]. </p><p></p><p class="bulletIndent1">This issue was addressed by a single institution retrospective study of 960 patients with CLL/SLL that identified an autoimmune cytopenia in 70 patients (7 percent) at some point during the disease process [<a href="#rid7">7</a>]. Patients who were classified as Binet stage C due to autoimmune cytopenias had longer median survival than patients with cytopenias due to bone marrow infiltration (7 versus 4 years) and a worse median survival than those with stage A disease (7 versus 10 years). Many patients with autoimmune cytopenias were able to normalize their blood counts after therapy directed at the autoimmune process and thereby postpone the initiation of chemotherapy.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Rai staging system</span><span class="headingEndMark"> — </span>The Rai staging system uses physical examination and complete blood count to stratify patients into three risk groups, which can be further subdivided into five stages with different estimated OS  (<a class="graphic graphic_table graphicRef56284" href="/z/d/graphic/56284.html" rel="external">table 1</a>). While the prognostic value of the Rai staging system remains, the estimated median OS by stage has improved dramatically as treatments have evolved.</p><p>In the original series published in 1975, the percentage of patients in each stage and estimated median OS were as follows [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Low risk</p><p class="bulletIndent2"><span class="glyph">•</span>Stage 0 – Lymphocytosis alone (18 percent; historical median OS &gt;150 months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk</p><p class="bulletIndent2"><span class="glyph">•</span>Stage I – Lymphadenopathy (23 percent; historical median OS 101 months)</p><p class="bulletIndent2"><span class="glyph">•</span>Stage II – Enlarged liver and/or spleen (31 percent; historical median OS 71 months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk</p><p class="bulletIndent2"><span class="glyph">•</span>Stage III – Hemoglobin &lt;11 g/dL (17 percent; historical median OS 19 months)</p><p class="bulletIndent2"><span class="glyph">•</span>Stage IV – Platelet count &lt;100,000/microL (11 percent; historical median OS 19 months)</p><p></p><p>The percentage of patients with stage 0 disease at diagnosis may differ depending on the use of "routine" laboratory testing with complete blood counts.</p><p>Although the initial report noted that there were only three distinct actuarial survival patterns (stage 0, stages I and II combined, and stages III and IV combined), they recommended that the five-stage system be maintained to investigate prospectively whether biological and clinical differences would emerge between stages I and II and between stages III and IV. It became apparent in the 1980s, however, that it was impractical to stratify patients in five categories for prospective randomized trials and the staging system was modified to consist of three risk groups (low, intermediate, and high) [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Binet staging system</span><span class="headingEndMark"> — </span>The Binet staging system uses physical examination and complete blood count to stratify patients into three risk groups with different estimated OS  (<a class="graphic graphic_table graphicRef80421" href="/z/d/graphic/80421.html" rel="external">table 2</a>). While the prognostic value of the Binet staging system remains, the estimated median OS by stage has improved dramatically as treatments have evolved. </p><p>Data from the original series published in 1981 were as follows [<a href="#rid2">2,9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage A (low risk) – &lt;3 involved lymphoid sites (median OS comparable to age-matched controls)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage B (intermediate risk) – ≥3 involved lymphoid sites (historical median OS 84 months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage C (high risk) – Hemoglobin &lt;10 g/dL and/or platelets &lt;100,000/microL (historical median OS 24 months)</p><p></p><p>To determine Binet stage, physical examination evaluates five potential sites of lymphoid involvement: cervical, axillary, and inguinal lymph nodes (whether unilateral or bilateral, each area is counted as one), plus<strong> </strong>spleen and liver. Lymph node enlargement is defined as ≥1 cm.</p><p>Computed tomography (CT) of the chest, abdomen, and pelvis is not routinely performed as part of the staging of patients with CLL/SLL outside of a clinical trial, but it may be indicated based on the patient's symptoms [<a href="#rid10">10</a>]. CT scans may reveal enlargement of retroperitoneal or mediastinal nodes that are not included<strong> </strong>for determining palpable enlargement among the five sites of enlarged lymphoid areas.</p><p class="headingAnchor" id="H881370989"><span class="h1">PROGNOSTIC VERSUS PREDICTIVE MARKERS</span><span class="headingEndMark"> — </span>Prognostic and predictive markers are measurable variables associated with disease outcome. They may be a single measurement (eg, <em>TP53</em> mutation) or a combination of measurements (eg, Rai staging system). Whether a marker is prognostic, predictive, or both impacts its potential role in patient care [<a href="#rid11">11,12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic markers</strong> – Prognostic markers are associated with clinical outcomes (eg, progression-free survival, overall survival) independent of therapy received. Such markers usually reflect tumor burden, distribution, and growth rate. </p><p></p><p class="bulletIndent1">As an example, in CLL/SLL, the Rai staging system is a prognostic marker  (<a class="graphic graphic_table graphicRef56284" href="/z/d/graphic/56284.html" rel="external">table 1</a>). Patients with a higher Rai stage will have a worse outcome than those with a lower Rai stage. This difference in predicted outcome is seen regardless of therapy chosen (eg, in patients receiving chemoimmunotherapy and in patients receiving targeted therapies). (See <a class="local">'Rai staging system'</a> above.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive markers</strong> – Predictive markers inform the likelihood of response to a given treatment and therefore impact choice of therapy. Such markers may be the target of the treatment or may modify the expression and/or function of the target. </p><p></p><p class="bulletIndent1">As an example, in CLL/SLL, del(17p) and <em>TP53</em> mutation are used as predictive markers to guide therapy. CLL/SLL tumors with del(17p) or <em>TP53</em> mutation have an impaired DNA damage response pathway and do not respond to chemoimmunotherapy but do respond to therapies that act through mechanisms independent of this pathway (eg, targeted therapies). (See <a class="local">'Del(17p) or TP53 mutations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Markers may be both prognostic and predictive</strong> – Some markers are both prognostic and predictive. </p><p></p><p class="bulletIndent1">As an example, in CLL/SLL, del(17p) and <em>TP53</em> mutation appear to be both predictive and prognostic. While targeted therapies are superior to chemoimmunotherapy in this population, del(17p) and <em>TP53</em> mutation retain their prognostic impact; patients with del(17p) or <em>TP53</em> mutation treated with targeted agents have inferior outcomes when compared with other patients without either del(17p) or <em>TP53</em> mutations and treated with these same agents [<a href="#rid13">13</a>]. </p><p></p><p class="headingAnchor" id="H2705132332"><span class="h1">PREDICTIVE MARKERS</span><span class="headingEndMark"> — </span>Predictive markers inform the likelihood of outcome to a given treatment, and therefore impact choice of therapy. We have incorporated predictive markers into our preferred initial therapy  (<a class="graphic graphic_algorithm graphicRef122052" href="/z/d/graphic/122052.html" rel="external">algorithm 1</a>) and management of relapsed or refractory CLL  (<a class="graphic graphic_algorithm graphicRef129414" href="/z/d/graphic/129414.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef129417" href="/z/d/graphic/129417.html" rel="external">table 3</a>). </p><p class="headingAnchor" id="H2765720017"><span class="h2">Del(17p) or TP53 mutations</span><span class="headingEndMark"> — </span><em>TP53</em> is a tumor-suppressor gene located on the short arm of chromosome 17; it can be inactivated by deletion and/or point mutation. Testing for del(17p) and <em>TP53</em> mutations is a routine part of the pretreatment evaluation of CLL/SLL before every new line of therapy to detect clonal evolution, and it impacts our choice of therapy  (<a class="graphic graphic_algorithm graphicRef122052" href="/z/d/graphic/122052.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef129414" href="/z/d/graphic/129414.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef129417" href="/z/d/graphic/129417.html" rel="external">table 3</a>). In CLL/SLL, del(17p) and <em>TP53</em> mutation are both predictive of worse clinical outcomes with chemoimmunotherapy as compared to targeted therapies (eg, BTK or BCL2 inhibitors)  (<a class="graphic graphic_figure graphicRef108430" href="/z/d/graphic/108430.html" rel="external">figure 1</a>), and they are prognostic for patients treated with all available therapies.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection</strong> – Del(17p) is evaluated with fluorescence in situ hybridization (FISH) of the peripheral blood. <em>TP53</em> mutation can be evaluated with Sanger sequencing or next-generation sequencing (NGS). While NGS increases sensitivity, it also increases the false positive rate.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of abnormalities</strong> – Using FISH techniques, deletions of 17p are found in 7 to 10 percent of treatment-naïve patients with CLL/SLL and in a much higher proportion of those with relapsed or refractory disease [<a href="#rid14">14,15</a>]. <em>TP53</em> gene mutations are identified in 10 to 47 percent of patients with CLL/SLL, depending on disease phase and prior therapy [<a href="#rid16">16-22</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive value</strong> – CLL/SLL tumors with del(17p) or <em>TP53</em> mutation have an impaired DNA damage response pathway and do not respond durably to chemoimmunotherapy, but they do respond to therapies that act through mechanisms independent of this pathway (eg, targeted therapies). While the predictive value of del(17p) and <em>TP53</em> mutation has not been formally evaluated in a randomized trial, it is widely accepted as a predictive marker based on the magnitude of effect in nonrandomized comparisons. (See  <a class="medical medical_review" href="/z/d/html/4539.html" rel="external">"Pathobiology of chronic lymphocytic leukemia", section on 'Impaired DNA damage response'</a>.) </p><p></p><p class="bulletIndent1">The choice of therapy in patients with del(17p) or <em>TP53</em> mutation is discussed in detail separately  (<a class="graphic graphic_algorithm graphicRef122052" href="/z/d/graphic/122052.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/83749.html" rel="external">"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Del(17p) and/or TP53 mutations (very high risk)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic value</strong> – While targeted therapies are superior to chemoimmunotherapy in this population, del(17p) and <em>TP53</em> mutation retain their prognostic impact; patients with del(17p) or <em>TP53</em> mutation treated with targeted agents have inferior outcomes when compared with other patients treated with these same agents [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H472101095"><span class="h2">IGHV mutation status, ZAP-70, and CD38</span><span class="headingEndMark"> — </span>Testing for immunoglobulin heavy chain variable region (IGHV) gene mutation status is a routine part of the pretreatment evaluation of CLL/SLL, as IGHV mutation status can impact the choice of therapy  (<a class="graphic graphic_algorithm graphicRef122052" href="/z/d/graphic/122052.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef129414" href="/z/d/graphic/129414.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef129417" href="/z/d/graphic/129417.html" rel="external">table 3</a>). IGHV gene mutation status does not change with disease evolution and does not need to be retested at progression. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detection</strong> – IGHV mutation status can be tested on the peripheral blood or bone marrow. IGHV is usually evaluated with Sanger sequencing, and it is compared with germline genes available in immunoglobulin databases [<a href="#rid23">23,24</a>]. Mutated IGHV genes are defined in most studies as having a &gt;2 percent difference in nucleotide sequence compared with germline DNA [<a href="#rid25">25,26</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of abnormalities</strong> – Approximately half of CLL/SLL tumors have mutated IGHV genes [<a href="#rid5">5,25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive value </strong>– In CLL/SLL, the IGHV gene mutation status is predictive of outcomes following chemoimmunotherapy as compared to targeted therapy. In prospective trials with long follow-up, a subset of patients with IGHV-mutated CLL/SLL obtain prolonged durable remissions after chemoimmunotherapy [<a href="#rid27">27-29</a>]. These durable remissions are not seen in patients with IGHV-unmutated CLL/SLL. (See  <a class="medical medical_review" href="/z/d/html/83749.html" rel="external">"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Immunoglobulin heavy chain variable mutated (standard risk)'</a>.)</p><p></p><p class="bulletIndent1">In the CLL14 trial, unmutated IGHV was identified as a predictive biomarker for increased benefit of <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a> over obinutuzumab plus <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic value</strong> – Unmutated IGHV genes are associated with shorter time to initial therapy, higher risk of relapse following chemoimmunotherapy and hematopoietic cell transplantation, and shorter overall survival [<a href="#rid5">5,25,26,30-38</a>]. In one study of 325 consecutive patients with CLL/SLL, the presence of unmutated IGHV genes was associated with a hazard ratio of death of 5.3 (95% CI 2.7-10), as compared with those with mutated IGHV genes [<a href="#rid33">33</a>].</p><p></p><p>Expression of zeta chain associated protein 70 (ZAP-70) and CD38 are imperfect surrogates for IGHV mutation status. In multiple studies, increased expression of ZAP-70 and CD38 are associated with unmutated IGHV genes, higher clinical stage, greater tendency for disease progression, a poor response to treatment, and shorter survival [<a href="#rid25">25,39-48</a>]. However, correlation is not perfect. In addition, the best cutoff value for determining ZAP-70 positivity is unclear and levels appear to change over time, while IGHV mutation status remains constant [<a href="#rid49">49</a>]. </p><p>The relationships among lymphocyte developmental stage and morphology, CD38 and ZAP-70 positivity, genetic studies (eg, chromosomal changes, gene expression profiling, IGHV gene mutation status, microRNA signatures), and other cellular variables as important prognostic features are complex and the subject of considerable ongoing interest [<a href="#rid50">50-63</a>]. </p><p class="headingAnchor" id="H2756309199"><span class="h2">NOTCH1 mutations</span><span class="headingEndMark"> — </span>Testing for <em>NOTCH1 </em>mutations is not routinely performed in CLL/SLL, and the predictive and prognostic value of <em>NOTCH1 </em>mutations is controversial. Confirmatory trials are required to determine whether <em>NOTCH1 </em>status should impact treatment choice.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of abnormalities</strong> – Mutations in <em>NOTCH1</em> can be found in 4 to 13 percent of patients with CLL/SLL [<a href="#rid22">22,64-70</a>]. NOTCH1 mutations are virtually mutually exclusive with <em>SF3B1</em> mutations [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive value</strong> – Some studies suggest that <em>NOTCH1</em> mutations are predictive of worse clinical outcomes following therapies that target CD20, while other have not. The impact may differ with the specific anti-CD20 therapy used. In a subgroup analysis of the CLL8 study, CLL/SLL with <em>NOTCH1</em> mutation did not appear to benefit from the addition of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> to treatment with <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid30">30</a>]. However, other studies suggest that CLL/SLL with <em>NOTCH1</em> mutation does benefit from <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">obinutuzumab</a> [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic value</strong> – <em>NOTCH1</em> mutations are associated with unmutated IGHV and it is unclear whether it is an independent prognostic marker [<a href="#rid71">71</a>]. </p><p></p><p class="headingAnchor" id="H982425882"><span class="h2">BTK, PLCg2, and BCL2 mutations</span><span class="headingEndMark"> — </span>Testing for mutations of genes in the B cell receptor (BCR) pathway (BTK and PLCg2) and BCL2 can inform treatment at the time of disease progression  (<a class="graphic graphic_algorithm graphicRef129414" href="/z/d/graphic/129414.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef129417" href="/z/d/graphic/129417.html" rel="external">table 3</a>). Mutations in these pathways are uncommon at the time of CLL/SLL diagnosis, and testing at diagnosis is not indicated [<a href="#rid72">72</a>]. However, a percentage of CLL/SLL tumors that progress on targeted therapy will have mutations in the target, which impact choice of subsequent therapy. (See  <a class="medical medical_review" href="/z/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Choice of therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><em>BTK</em> and <em>PLCg2</em> mutations – Following treatment that targets the BCR pathway, mutations in <em>BTK</em> and <em>PLCg2</em> are assumed to be predictive of worse clinical outcomes with BCR inhibitors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>BCL2</em> mutations – Following treatment with <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">venetoclax</a>, mutations in <em>BCL2</em> are assumed to be predictive of worse outcomes upon retreatment with venetoclax-based therapy.</p><p></p><p>Initial studies suggest that many CLL/SLL progressions on <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">acalabrutinib</a>, and <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">zanubrutinib</a> are characterized by point mutations (eg, <em>BTK</em> C481S) that disrupt the covalent binding of these agents to BTK or point mutations in phospholipase Cy2 (PLCg2), which plays a role in BCR signaling [<a href="#rid73">73-77</a>]. These mutations are not detectable before therapy but are selected for during BTK inhibitor treatment in a proportion of patients. The <em>BTK</em> C481 mutation does not block binding of noncovalent, reversible-binding BTK inhibitors such as <a class="drug drug_general" data-topicid="140692" href="/z/d/drug information/140692.html" rel="external">pirtobrutinib</a>; however, CLL/SLL progressions on pirtobrutinib have demonstrated novel, non-C481 <em>BTK</em> mutations that confer resistance to noncovalent BTK inhibitors and some covalent BTK inhibitors [<a href="#rid78">78,79</a>]. </p><p>Similarly, <em>BCL2</em> gene mutations can be detected in a percentage of CLL/SLL tumors that progress on long-term BCL2-directed therapy (ie, <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">venetoclax</a>) [<a href="#rid80">80-83</a>]. </p><p class="headingAnchor" id="H8"><span class="h1">PROGNOSTIC MARKERS</span><span class="headingEndMark"> — </span>Prognostic markers are associated with clinical outcomes (eg, progression-free survival [PFS], overall survival [OS]) independent of therapy received. Such markers usually reflect tumor burden, distribution, and growth rate. </p><p>As described separately, the Rai and Binet staging systems use physical examination and complete blood count to stratify patients into three risk groups (low, intermediate, and high) and provide prognostic information for patient care. Both systems are in wide use in clinical practice and are described in detail separately. (See <a class="local">'Clinical staging'</a> above.)</p><p>However, clinical staging is imperfect. Some patients classified as having early-stage disease progress rapidly. Other prognostic markers have been investigated to identify these patients  (<a class="graphic graphic_table graphicRef74103" href="/z/d/graphic/74103.html" rel="external">table 4</a>). Some have been incorporated into prognostic scores.</p><p>The main markers that are used clinically are:</p><p class="bulletIndent1"><span class="glyph">●</span>Rai and Binet clinical staging (see <a class="local">'Clinical staging'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Del(17p) and <em>TP53</em> mutation status (see <a class="local">'Del(17p) or TP53 mutations'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin heavy chain variable region (IGHV) gene mutation status (see <a class="local">'IGHV mutation status, ZAP-70, and CD38'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte doubling time (see <a class="local">'Lymphocyte doubling time'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta-2 microglobulin (see <a class="local">'Beta-2 microglobulin'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Del(11q), del(13q), and trisomy 12 (see <a class="local">'Genomic abnormalities'</a> below)</p><p></p><p>The clinical use of other prognostic markers (eg, CD38, ZAP-70, <em>NOTCH1, BIRC3, </em>and<em> SF3B1</em> mutation) is less clear.</p><p>Several prognostic factors have been tested and found to be of limited, if any, usefulness in predicting the course of nonadvanced stages of CLL [<a href="#rid3">3,84</a>]. These prognostic factors include: morphologic features of blood lymphocytes (ie, the relative proportion of prolymphocytes [<a href="#rid85">85,86</a>]), phenotypic profile of B-lymphocytes, and levels of serum immunoglobulins [<a href="#rid87">87,88</a>].</p><p class="headingAnchor" id="H2456281030"><span class="h2">Prognostic scores</span></p><p class="headingAnchor" id="H1828861635"><span class="h3">Scores for early-stage CLL</span><span class="headingEndMark"> — </span>Prognostic scores have been developed to predict time to first treatment for patients presenting with early-stage CLL (Rai stage 0, I, or II or Binet stage A).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLL1-PM</strong> – The CLL1 prognostic model (CLL1-PM) uses a weighted point system with six variables to stratify patients with early-stage CLL/SLL observed at diagnosis [<a href="#rid89">89,90</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Del(17p) – 3.5 points</p><p class="bulletIndent2"><span class="glyph">•</span>Unmutated IGHV – 2.5 points</p><p class="bulletIndent2"><span class="glyph">•</span>Del(11q) – 2.5 points </p><p class="bulletIndent2"><span class="glyph">•</span>Serum beta-2 microglobulin &gt;3.5 mg/L – 2.5 points </p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocyte doubling time &lt;12 months – 1.5 points </p><p class="bulletIndent2"><span class="glyph">•</span>Age &gt;60 years – 1.5 points</p><p></p><p class="bulletIndent1">These variables separate patients into four risk groups with differing likelihood of treatment-free survival (TFS) at 5 and 10 years:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very low risk (0 to 1.5 points) – 86 and 67 percent 5- and 10-year TFS; median not reached</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low risk (2 to 4 points) – 52 and 26 percent 5- and 10-year TFS; median 64 months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High risk (4.5 to 6.5 points) – 28 and 3 percent 5- and 10-year TFS; median 41 months</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very high risk (7 to 14 points) – 11 and 0 percent 5- and 10-year TFS; median 28 months</p><p></p><p class="bulletIndent1">The CLL1-PM was developed using data from 539 patients with Binet stage A CLL enrolled on the prospective CLL1 trial. These factors were also independent predictors of OS, although standard therapy at the time was chemoimmunotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IPS-E</strong> – The International Prognostic Score for Early-stage CLL (IPS-E) uses three variables to stratify patients with early-stage CLL/SLL at diagnosis [<a href="#rid91">91</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unmutated IGHV</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocytes &gt;15,000/microL (&gt;15 x 10<sup>9</sup>/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Palpable lymph nodes </p><p></p><p class="bulletIndent1">These variables separate patients three risk groups with differing likelihood of requiring treatment at one and five years:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low risk (no risk factors) – &lt;1 percent treated at 1 year; 8 percent treated at 5 years</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intermediate risk (one risk factor) – 3 percent treated at 1 year; 28 percent treated at 5 years</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High risk (two or three risk factors) – 14 percent treated at 1 year; 61 percent treated at 5 years   </p><p></p><p class="bulletIndent1">The IPS-E was developed and validated using individual patient data from 11 international cohorts of approximately 5000 patients with early-stage CLL (Rai stage 0, I, or II or Binet stage A) initially managed with active surveillance [<a href="#rid91">91</a>]. Unmutated IGHV, lymphocytes &gt;15,000/microL, and palpable lymph nodes consistently and independently correlated with time to first treatment with similar magnitude allowing for equal weighting. In contrast, del(17p) and <em>TP53</em> mutation were not prognostic for time to first treatment even though these are important predictors of treatment response and help guide the choice of therapy once indicated.</p><p></p><p class="headingAnchor" id="H1112469802"><span class="h3">Four factor prognostic model for ibrutinib</span><span class="headingEndMark"> — </span>The four factor prognostic model for <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> assigns one point for each of the following variables  (<a class="graphic graphic_table graphicRef131543" href="/z/d/graphic/131543.html" rel="external">table 5</a>) [<a href="#rid92">92</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Del(17p) or <em>TP53</em> mutation</p><p class="bulletIndent1"><span class="glyph">●</span>Serum beta-2 microglobulin ≥5 mg/L  </p><p class="bulletIndent1"><span class="glyph">●</span>Lactate dehydrogenase &gt;250 units/L</p><p class="bulletIndent1"><span class="glyph">●</span>Relapsed or refractory disease </p><p></p><p>The sum of these points determines the prognostic score, which separates patients into three risk groups with different estimated PFS and OS following treatment with <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk (0 to 1 points) – 87 percent 3-year PFS; 93 percent 3-year OS</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk (2 points) – 74 percent 3-year PFS; 83 percent 3-year OS</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk (3 to 4 points) – 47 percent 3-year PFS; 63 percent 3-year OS</p><p></p><p>The scoring system was developed and validated using data from patients treated with <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> on several industry sponsored trials and underwent external validation using data from a single center investigator-initiated phase II trial. The prognostic value was maintained when applied to individual cohorts of patients with treatment-naïve or relapsed/refractory disease, and it was superior to the CLL international prognostic index (CLL-IPI) in this population. The three risk groups also had different likelihoods of developing mutations in <em>BTK</em> and <em>PLCg2</em> (17, 40, and 50 percent, respectively) and undergoing histologic transformation (0, 5, and 17 percent, respectively). Other groups have also validated the four factor prognostic score in other cohorts treated with ibrutinib [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H2259476209"><span class="h3">CLL-IPI</span><span class="headingEndMark"> — </span>The CLL international prognostic index (CLL-IPI) incorporates data regarding disease stage, biology, and patient-related factors. It was developed using data from patients receiving chemoimmunotherapy (CIT) and it is unknown whether the prognostic value will be maintained with targeted therapies.</p><p>A weighted point system is used to assess the following prognostic variables [<a href="#rid71">71</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Del(17p) or <em>TP53</em> mutation – 4 points</p><p class="bulletIndent1"><span class="glyph">●</span>Serum beta-2 microglobulin &gt;3.5 mg/L – 2 points </p><p class="bulletIndent1"><span class="glyph">●</span>Unmutated IGHV – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate- or high-risk Rai or Binet stage – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;65 years – 1 point</p><p></p><p>The sum of these points determines the prognostic score, which separates patients into four risk groups with different estimated OS in the original cohort:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk (0 to 1 points) – 91 and 87 percent 5- and 10-year OS; median not reached</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk (2 to 3 points) – 80 and 40 percent 5- and 10-year OS; median 104 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk (4 to 6 points) – 53 and 16 percent 5- and 10-year OS; median 63 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high risk (7 to 10 points) – 19 and 0 percent 5- and 10-year OS; median 31 months</p><p></p><p>The scoring system was developed and validated using data from 3472 previously untreated patients enrolled on one of eight phase 3 clinical trials of CIT completed between 1997 and 2007 [<a href="#rid71">71</a>]. The type of first-line CIT treatment was not identified as an independent factor in this analysis; however, the studies did not include treatment with novel oral inhibitors (eg, <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">idelalisib</a>, <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">acalabrutinib</a>, <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">venetoclax</a>), which have demonstrated activity in patients with del(17p) or <em>TP53</em> mutations. </p><p>The ability of this scoring system to prognosticate OS and time to first treatment has also been validated in independent cohorts of patients with newly diagnosed and previously untreated patients with CLL/SLL [<a href="#rid94">94-97</a>]. In a meta-analysis of several trials, the percentage of patients remaining treatment-free at five years after diagnosis decreased with increasing CLL-IPI risk group (82 percent low risk, 45 percent intermediate risk, 30 percent high risk, and 16 percent very high risk) [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H822079411"><span class="h2">Individual factors</span></p><p class="headingAnchor" id="H9"><span class="h3">Lymphocyte doubling time</span><span class="headingEndMark"> — </span>The lymphocyte doubling time (LDT) is the number of months it takes the absolute lymphocyte count to double. An actual or projected LDT in untreated patients &lt;12 months is associated with more aggressive disease, and a longer LDT is associated with an indolent course [<a href="#rid43">43,44,98</a>]. While LDT is useful in estimating disease tempo in patients not requiring immediate treatment, application in more advanced disease is limited because it takes time to measure. Clinical application is described separately. (See  <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia", section on 'Initial observation as standard care'</a>.)</p><p class="headingAnchor" id="H1728342532"><span class="h3">Beta-2 microglobulin</span><span class="headingEndMark"> — </span>Beta-2 microglobulin (B2M) levels correlate with disease stage and tumor burden in patients with CLL/SLL, with increasing levels associated with a poorer prognosis [<a href="#rid5">5,30,99-101</a>]. B2M is incorporated into several prognostic scores for CLL. (See <a class="local">'Prognostic scores'</a> above.)</p><p>B2M may be regulated, at least in part, by exogenous cytokines [<a href="#rid102">102</a>]. The source of these elevated cytokines in CLL/SLL is unclear, although interleukin (IL)-6, which inhibits apoptosis in CLL/SLL cells, may be released from vascular endothelium [<a href="#rid103">103</a>]. B2M levels also rise with worsening renal dysfunction leading some investigators to suggest a measure of B2M adjusted for the glomerular filtration rate [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Genomic abnormalities</span><span class="headingEndMark"> — </span>Genomic abnormalities as detected by fluorescence in situ hybridization (FISH) are present in most CLL/SLL tumors at diagnosis, and additional abnormalities are acquired with disease evolution. Our understanding regarding the prognostic value of specific cytogenetic and molecular findings in CLL/SLL is rapidly changing. While initial attempts have been made to incorporate this information into clinical practice, these will undoubtedly change as the impact of combinations of molecular findings is analyzed further. </p><p>In the pretreatment evaluation of patients with CLL/SLL, we routinely perform FISH of the peripheral blood for the following four common chromosomal abnormalities that can be detected in approximately 80 percent of CLL tumors [<a href="#rid14">14,105,106</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Del(13q14) – (See <a class="local">'Del(13q14)'</a> below.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trisomy 12 – (See <a class="local">'Trisomy 12'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Del(17p12) – (See <a class="local">'Del(17p) or TP53 mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Del(11q22-23) – (See <a class="local">'Del(11q)'</a> below.)</p><p></p><p>In addition, we assess the following genetic abnormalities which help guide therapy  (<a class="graphic graphic_algorithm graphicRef122052" href="/z/d/graphic/122052.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><em>TP53</em> mutation – (See <a class="local">'Del(17p) or TP53 mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IGHV gene mutation status – (See <a class="local">'IGHV mutation status, ZAP-70, and CD38'</a> above.)</p><p></p><p>Studies evaluating the prognostic impact of genetic abnormalities in CLL/SLL have had disparate results, which may be due to small sample size, variation in the timing of sample collection, and heterogeneity of treatments used. </p><p>Experts agree on the prognostic value of del(17p), <em>TP53</em> mutation, del(11q), unmutated IGHV, del(13) as a sole abnormality, and trisomy 12. Further study is needed to confirm the prognostic value of other biomarkers, including mutations in <em>BIRC3</em>, <em>SAMHD1</em>, <em>RPS15</em>, <em>NFKBIE</em>, <em>EGR2</em>, <em>KRAS</em>, and <em>POT1</em>, in particular in the era of targeted therapy. </p><p>For each biomarker, it is important for future studies to assess whether the prognostic value remains in the context of new therapies.</p><p class="headingAnchor" id="H304200589"><span class="h4">Del(17p)</span><span class="headingEndMark"> — </span>Del(17p) is found in 7 to 10 percent of treatment-naïve patients with CLL/SLL and in a much higher proportion of those with relapsed or refractory disease [<a href="#rid14">14,15</a>]. Del(17p) is both predictive of worse clinical outcomes with chemoimmunotherapy as compared to targeted therapies (eg, BTK or BCL2 inhibitors)  (<a class="graphic graphic_figure graphicRef108430" href="/z/d/graphic/108430.html" rel="external">figure 1</a>) and prognostic for patients treated with all available therapies. (See <a class="local">'Del(17p) or TP53 mutations'</a> above.)</p><p class="headingAnchor" id="H3010553328"><span class="h4">Del(11q)</span><span class="headingEndMark"> — </span>Del(11q22-q23) is present in 10 to 20 percent of patients with CLL/SLL [<a href="#rid14">14,46</a>]. CLL/SLL with del(11q) has an intermediate risk prognosis. </p><p>Historically, patients with del(11q) have been at high risk of either not responding to initial treatment or relapsing soon after achieving remission. The prognosis of patients with del(11q) has improved with the use of <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. Even so, outcomes are expected to be better with targeted therapies.</p><p>An analysis of patients enrolled on the randomized CLL8 trial evaluating the addition of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> to <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (FCR) in previously untreated CLL/SLL, identified 17p deletion, <em>TP53</em> mutation, 11q deletion, <em>SF3B1</em> mutation, unmutated IGHV, and elevated thymidine kinase as independent markers that were associated with short PFS following initial treatment [<a href="#rid30">30</a>]. All but 11q deletion were also prognostic factors of short OS along with older age, poor performance status, and elevated B2M. Median PFS rates following FCR for those with del(17p), <em>TP53</em> mutations, del(11q), or normal cytogenetics were approximately 12, 15, 50, and 50 months, respectively.</p><p>In another study of patients treated with non-targeted therapy, CLL/SLL with del(11q) in the absence of <em>TP53</em> and <em>BIRC3</em> was associated with an estimated survival at 5 and 10 years of 66 and 37 percent, respectively (compared with 78 and 58 percent for low-risk disease) [<a href="#rid107">107</a>]. The 10-year life expectancy was approximately half of that expected in a matched sample from the general population without CLL/SLL.</p><p>Chromosome 11q contains the ataxia telangiectasia mutated (<em>ATM</em>) gene (mapped to chromosome 11q22.3). The ATM gene product is involved in the detection of DNA damage and plays an important role in cell cycle progression. CLL/SLL cells without normal ATM function are unable to respond appropriately to chemotherapy-induced DNA damage. (See  <a class="medical medical_review" href="/z/d/html/4539.html" rel="external">"Pathobiology of chronic lymphocytic leukemia", section on 'Impaired DNA damage response'</a>.)</p><p class="headingAnchor" id="H1900633279"><span class="h4">Del(13q14)</span><span class="headingEndMark"> — </span>Del(13q14) is detected in 50 to 60 percent of CLL/SLL tumors [<a href="#rid14">14,46</a>]. When present as the sole abnormalities, monoallelic or biallelic 13q abnormalities appear to be associated with a favorable outcome [<a href="#rid14">14,108</a>].</p><p>In a large study of outcomes following non-targeted therapy, patients with del(13q14) as the sole genetic lesion had an estimated 10-year life expectancy that was similar to that expected in a matched sample from the general population without CLL/SLL [<a href="#rid107">107</a>].</p><p>The deleted region contains miR15A and miR16A microRNA [<a href="#rid109">109</a>]. These microRNA regulate the expression of proteins involved in apoptosis and the cell cycle. Without them, the cells do not respond appropriately to stress signals that should induce apoptosis. The B cell leukemia/lymphoma 2 (<em>BCL2</em>) gene encodes the antiapoptotic protein BCL2, and is one of the genes upregulated when these microRNA are deleted [<a href="#rid109">109</a>]. (See  <a class="medical medical_review" href="/z/d/html/4539.html" rel="external">"Pathobiology of chronic lymphocytic leukemia", section on 'Upregulation of BCL2 proto-oncogene'</a>.)  </p><p class="headingAnchor" id="H2186627298"><span class="h4">Trisomy 12</span><span class="headingEndMark"> — </span>Trisomy 12 is detected in 10 to 20 percent of CLL/SLL tumors. The prognostic value of trisomy 12 detected by FISH is not clear. </p><p>One study using FISH found an association of trisomy 12 with advanced disease and higher proliferative activity [<a href="#rid110">110</a>], while another study found that median survival in patients with CLL/SLL and trisomy 12 detected by FISH was similar to that of patients with CLL/SLL and a normal karyotype [<a href="#rid14">14</a>]. </p><p>In a large study of outcomes following non-targeted therapy, patients with trisomy 12 and those without genetic lesions were considered to have low-risk disease, although 10-year life expectancy was approximately 70 percent of that expected in a matched sample from the general population without CLL/SLL [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H2010712470"><span class="h4">Complex karyotype</span><span class="headingEndMark"> — </span>Metaphase cytogenetic testing is not routinely performed on CLL/SLL cells. It is technically challenging and requires specifically stimulated cultures since the majority of CLL/SLL cells are in G0/G1 phase of the cell cycle. However, accumulating evidence suggests that complex karyotype may be an independent marker of worse prognosis [<a href="#rid111">111-116</a>]. Many studies have defined complex karyotype as the presence of at least three structural and/or numerical chromosomal aberrations on chromosome-banding analysis. </p><p>The largest study to evaluate the impact of complex karyotype was a multicenter, retrospective study of &gt;5000 patients with CLL/SLL using stimulated cultures [<a href="#rid113">113</a>]. The presence of five or more chromosomal aberrations was a marker of worse survival, independent of clinical stage, IGHV mutation status, and <em>TP53</em> aberration status. In contrast, the prognostic impact of having three or four aberrations was limited to those with <em>TP53</em> aberrations. Among those without <em>TP53</em> aberrations, survival was similar among those with zero to five aberrations. </p><p>These results suggest heterogeneity among those with traditionally defined complex karyotypes. However, this study had several limitations. It was a retrospective cohort with data collected outside of clinical trials with heterogeneous treatment not using modern targeted therapy. In addition, the number of patients with complex karyotype and without <em>TP53</em> aberrations was small. As such, correlations between survival and number of karyotype abnormalities are exploratory. Further study is needed to better understand whether the identification of a complex karyotype should impact treatment decisions.</p><p class="headingAnchor" id="H359017875"><span class="h4">TP53 mutations</span><span class="headingEndMark"> — </span><em>TP53</em> gene mutations are identified in 10 to 47 percent of patients with CLL/SLL, depending on disease phase and prior therapy [<a href="#rid16">16-22</a>]. <em>TP53</em> mutations are both predictive of worse clinical outcomes with chemoimmunotherapy as compared to targeted therapies (eg, BTK or BCL2 inhibitors)  (<a class="graphic graphic_figure graphicRef108430" href="/z/d/graphic/108430.html" rel="external">figure 1</a>) and prognostic for patients treated with all available therapies. (See <a class="local">'Del(17p) or TP53 mutations'</a> above.)</p><p class="headingAnchor" id="H2949262653"><span class="h4">SF3B1 mutations</span><span class="headingEndMark"> — </span>Testing for <em>SF3B1</em> mutations is not routinely performed in CLL/SLL outside of a clinical trial.</p><p><em>SF3B1</em> mutations (most commonly K700E) can be identified in 15 to 18 percent of patients with CLL/SLL and are associated with a poor prognosis [<a href="#rid22">22,30,45,68,117-120</a>].</p><p>In an analysis of patients enrolled on the randomized CLL8 trial, <em>SF3B1</em> mutation was identified as an independent marker associated with worse PFS and OS following initial chemoimmunotherapy [<a href="#rid30">30</a>].</p><p>In another study of outcomes following non-targeted therapy, patients with <em>SF3B1</em> mutation in the absence of <em>TP53</em> and <em>BIRC3</em> abnormalities were considered to have intermediate-risk disease with estimated survival at 5 and 10 years of 66 and 37 percent, respectively (compared with 78 and 58 percent for those with low-risk disease) [<a href="#rid107">107</a>]. The 10-year life expectancy was approximately half of that expected in a matched sample from the general population without CLL/SLL.</p><p>The <em>SF3B1</em> gene encodes for part of a nuclear ribonucleoprotein that complexes with other nuclear ribonucleoproteins to create the spliceosome that is responsible for splicing messenger RNA. (See  <a class="medical medical_review" href="/z/d/html/4539.html" rel="external">"Pathobiology of chronic lymphocytic leukemia", section on 'Gene mutations'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Other markers</span><span class="headingEndMark"> — </span>Several other prognostic markers have been studied, but their actual place in clinical practice has not been established. A few of particular interest are described below. The prognostic value of some of these markers (eg, CD49d) are likely to be dependent on the specific therapies employed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free light chain assay</strong> – A prospective study of 339 patients with CLL/SLL reported that the 49 percent of patients who had abnormality in free light chain assays (eg, monoclonal, polyclonal, or kappa/lambda ratio abnormalities) had a shorter time to initial therapy than those with normal free light chain assays [<a href="#rid121">121</a>]. Patients with either monoclonal or polyclonal abnormalities had inferior OS when compared with those with normal or kappa/lambda only abnormalities. These results have been confirmed in another cohort [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D levels</strong> – Patients with CLL/SLL have a similar rate of vitamin D deficiency as that seen in the general population (approximately 30 to 40 percent). A prospective cohort analysis identified low vitamin D levels (&lt;25 ng/mL) as a marker of poor prognosis in 390 patients with newly diagnosed CLL/SLL and confirmed this prognostic value in a second cohort of 153 patients [<a href="#rid123">123</a>]. On multivariate analysis, vitamin D deficiency was associated with a shorter time to initiation of treatment (HR 1.47; 95% CI 1.11-1.96) and a trend toward shorter survival (HR 1.47; 95% CI 0.97-2.23). (See  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pattern of bone marrow infiltration</strong> – While not routinely performed, studies suggest that the pattern of lymphocyte infiltration in the bone marrow biopsy specimen is an independent prognostic marker. A diffuse pattern is associated with a progressive course and a non-diffuse (interstitial and nodular) pattern is associated with a more indolent course [<a href="#rid124">124-127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MicroRNAs</strong> – MicroRNAs (miRNAs) are small noncoding RNAs that modulate the expression of genes at the post-transcriptional level. The decreased expression of specific microRNAs (eg, miR-223 and miR-29c) and the increased expression of others (eg, miR-155) has been associated with reduced OS in retrospective analyses [<a href="#rid128">128-130</a>]. Confirmation in prospective trials is required to validate their prognostic value. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD49d expression</strong> – Increased expression of CD49d as detected by flow cytometry is associated with decreased TFS and OS [<a href="#rid131">131-134</a>]. The integrin CD49d interacts with receptors on endothelial cells (eg, VCAM-1) to modulate the homing of CLL cells to secondary organs and their interaction with the microenvironment [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum VEGF</strong> – An Italian study found that Binet stage A patients with low serum concentrations of vascular endothelial growth factor (VEGF) had a median PFS that was not reached at 40 months, significantly longer than patients with higher serum VEGF concentrations (median PFS 33 months) [<a href="#rid136">136</a>]. CLL cells have been shown to produce VEGF, which may be important for expansion of lymphoid tissues, migration of CLL cells from blood to tissues, and/or prolongation of the survival of these cells [<a href="#rid137">137</a>].</p><p></p><p class="headingAnchor" id="H2210680113"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120614.html" rel="external">"Society guideline links: Chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/687.html" rel="external">"Patient education: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has a heterogeneous natural history with survival times from initial diagnosis that range from approximately 2 to 20 years, and a median survival of approximately 10 years. Patients are often asymptomatic at diagnosis and able to maintain their usual lifestyle. CLL/SLL progresses at a variable rate to a terminal phase with worsening performance status and frequent complications from cytopenias. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical staging</strong> – The Rai and Binet clinical staging systems use physical examination and complete blood counts to stratify patients into three risk groups with differing expected disease tempo and overall survival  (<a class="graphic graphic_table graphicRef56284" href="/z/d/graphic/56284.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef80421" href="/z/d/graphic/80421.html" rel="external">table 2</a>). Imaging is not used for routine staging, but it should be performed in patients with signs or symptoms concerning for enlarged abdominal or pelvic nodes (eg, obstructive jaundice or obstruction of the inferior vena cava or ureters). (See <a class="local">'Clinical staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive markers</strong> – The following predictive markers inform the likelihood of response to a given treatment and therefore impact choice of therapy  (<a class="graphic graphic_algorithm graphicRef122052" href="/z/d/graphic/122052.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Del(17p) and </strong><strong><em>TP53</em></strong><strong> mutation</strong> – CLL/SLL tumors with del(17p) or <em>TP53</em> mutation have an impaired DNA damage response pathway and have poor outcome with chemoimmunotherapy, which is markedly improved by therapies that are independent of this pathway (eg, targeted therapies). While targeted therapies are superior to chemoimmunotherapy in this population, patients with del(17p) or <em>TP53</em> mutation treated with targeted agents have inferior outcomes when compared with other patients treated with these same agents. Testing for del(17p) and <em>TP53</em> mutations is a routine part of the pretreatment evaluation of CLL/SLL both at diagnosis and at progression to detect clonal evolution. (See <a class="local">'Del(17p) or TP53 mutations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IGHV mutation status</strong> – CLL/SLL tumors with mutated immunoglobulin heavy chain variable region (IGHV) genes have an indolent clinical course, and a subset obtain prolonged durable remissions after chemoimmunotherapy. In contrast, these durable remissions are not seen in patients with IGHV-unmutated CLL/SLL. IGHV gene mutation status does not change with disease evolution and does not need to be retested at progression. (See <a class="local">'IGHV mutation status, ZAP-70, and CD38'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic markers</strong> – Prognostic markers are associated with clinical outcomes (eg, progression-free survival, overall survival) independent of therapy received. Such markers usually reflect tumor burden, distribution, and growth rate. Several prognostic models have been proposed that combine several prognostic markers to predict outcomes in different populations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Observation of early-stage CLL/SLL</strong> – The CLL1 prognostic model (CLL1-PM) and the International Prognostic Score for Early-stage CLL (IPS-E) stratify patients with early-stage CLL/SLL to predict likelihood of requiring treatment at five years. (See <a class="local">'Scores for early-stage CLL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ibrutinib</strong> – The four factor prognostic model for <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> identifies those with three or four variables (17p aberration, beta-2 microglobulin ≥5 mg/L, lactate dehydrogenase &gt;250 units/L, and prior treatment) as those at high risk of early progression on ibrutinib  (<a class="graphic graphic_table graphicRef131543" href="/z/d/graphic/131543.html" rel="external">table 5</a>). (See <a class="local">'Four factor prognostic model for ibrutinib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemoimmunotherapy</strong> – The CLL international prognostic index (CLL-IPI) incorporates clinical stage, age, IGHV mutation status, del(17p), <em>TP53</em> mutation status, and serum beta-2 microglobulin to predict time to first treatment and overall survival following chemoimmunotherapy. It is unknown whether the prognostic value will be maintained with targeted therapies. (See <a class="local">'CLL-IPI'</a> above.)</p><p></p><p class="bulletIndent1">Prior to treatment, we routinely test for del(17p), <em>TP53</em> mutation, IGHV mutation status, beta-2 microglobulin, and lactate dehydrogenase. We repeat each of these tests prior to each new line of therapy with the exception of IGHV mutation status. We also test for mutations of genes in the B cell receptor (BCR) pathway (BTK and PLCg2) and BCL2 for patients progressing after therapies targeting BCR and BCL2, respectively  (<a class="graphic graphic_algorithm graphicRef129414" href="/z/d/graphic/129414.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef129417" href="/z/d/graphic/129417.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1">In addition, we routinely perform fluorescence in situ hybridization (FISH) of the peripheral blood for del(11q), trisomy 12, and del(13q). Of these, del(13q) and trisomy 12 are favorable prognostic findings. Del(11q) is intermediate risk. (See <a class="local">'Genomic abnormalities'</a> above.)</p><p></p><p class="headingAnchor" id="H1604477"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael J Keating, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219.</a></li><li><a class="nounderline abstract_t">Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198.</a></li><li><a class="nounderline abstract_t">Thomas R, Ribeiro I, Shepherd P, et al. Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol 2002; 116:341.</a></li><li><a class="nounderline abstract_t">Keating MJ, Scouros M, Murphy S, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2:157.</a></li><li><a class="nounderline abstract_t">Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124:49.</a></li><li><a class="nounderline abstract_t">Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008; 141:615.</a></li><li><a class="nounderline abstract_t">Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010; 116:4771.</a></li><li class="breakAll">Rai KR. A critical analysis of staging in CLL. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Direction, Robert P Gale, Rai Kanti (Eds), Alan R Liss, 1987. Vol 59, p.253.</li><li><a class="nounderline abstract_t">Binet JL, Leporrier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40:855.</a></li><li><a class="nounderline abstract_t">Blum KA, Young D, Broering S, et al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol 2007; 25:5624.</a></li><li><a class="nounderline abstract_t">Ballman KV. Biomarker: Predictive or Prognostic? J Clin Oncol 2015; 33:3968.</a></li><li><a class="nounderline abstract_t">Hayes DF. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. J Clin Oncol 2021; 39:238.</a></li><li><a class="nounderline abstract_t">Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood 2020; 135:2402.</a></li><li><a class="nounderline abstract_t">Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910.</a></li><li><a class="nounderline abstract_t">Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood 2015; 126:2110.</a></li><li><a class="nounderline abstract_t">Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85:1580.</a></li><li><a class="nounderline abstract_t">el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82:3452.</a></li><li><a class="nounderline abstract_t">Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88:5413.</a></li><li><a class="nounderline abstract_t">Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148.</a></li><li><a class="nounderline abstract_t">Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998; 91:4342.</a></li><li><a class="nounderline abstract_t">Barnabas N, Shurafa M, Van Dyke DL, et al. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer 2001; 91:285.</a></li><li><a class="nounderline abstract_t">Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497.</a></li><li><a class="nounderline abstract_t">Ghia P, Stamatopoulos K, Belessi C, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007; 21:1.</a></li><li><a class="nounderline abstract_t">Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia 2022; 36:1961.</a></li><li><a class="nounderline abstract_t">Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840.</a></li><li><a class="nounderline abstract_t">Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848.</a></li><li><a class="nounderline abstract_t">Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975.</a></li><li><a class="nounderline abstract_t">Strati P, Wierda W, Burger J, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 2013; 119:3805.</a></li><li><a class="nounderline abstract_t">Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127:303.</a></li><li><a class="nounderline abstract_t">Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123:3247.</a></li><li><a class="nounderline abstract_t">Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102:1515.</a></li><li><a class="nounderline abstract_t">Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101:2049.</a></li><li><a class="nounderline abstract_t">Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100:1410.</a></li><li><a class="nounderline abstract_t">Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99:2262.</a></li><li><a class="nounderline abstract_t">Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol 2008; 140:320.</a></li><li><a class="nounderline abstract_t">Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009; 113:3168.</a></li><li><a class="nounderline abstract_t">Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood 2015; 126:1921.</a></li><li><a class="nounderline abstract_t">Parikh SA, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood 2016; 127:1752.</a></li><li><a class="nounderline abstract_t">Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112:1923.</a></li><li><a class="nounderline abstract_t">Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100:4609.</a></li><li><a class="nounderline abstract_t">Claus R, Lucas DM, Ruppert AS, et al. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 2014; 124:42.</a></li><li><a class="nounderline abstract_t">Fong D, Kaiser A, Spizzo G, et al. Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine. Br J Haematol 2005; 129:199.</a></li><li><a class="nounderline abstract_t">Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60:2712.</a></li><li><a class="nounderline abstract_t">Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62:567.</a></li><li><a class="nounderline abstract_t">Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526:525.</a></li><li><a class="nounderline abstract_t">Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89:2516.</a></li><li><a class="nounderline abstract_t">Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood 2013; 121:4036.</a></li><li><a class="nounderline abstract_t">Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20:398.</a></li><li><a class="nounderline abstract_t">Dürig J, Nückel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17:2426.</a></li><li><a class="nounderline abstract_t">Degan M, Bomben R, Bo MD, et al. Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol 2004; 126:29.</a></li><li><a class="nounderline abstract_t">Haslinger C, Schweifer N, Stilgenbauer S, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22:3937.</a></li><li><a class="nounderline abstract_t">Dickinson JD, Smith LM, Sanger WG, et al. Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. Br J Haematol 2005; 128:460.</a></li><li><a class="nounderline abstract_t">Kienle DL, Korz C, Hosch B, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23:3780.</a></li><li><a class="nounderline abstract_t">Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105:4807.</a></li><li><a class="nounderline abstract_t">Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106:650.</a></li><li><a class="nounderline abstract_t">Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793.</a></li><li><a class="nounderline abstract_t">Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24:437.</a></li><li><a class="nounderline abstract_t">Kröber A, Bloehdorn J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24:969.</a></li><li><a class="nounderline abstract_t">Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108:1135.</a></li><li><a class="nounderline abstract_t">Dicker F, Schnittger S, Haferlach T, et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108:3152.</a></li><li><a class="nounderline abstract_t">Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006; 108:2950.</a></li><li><a class="nounderline abstract_t">Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98:2633.</a></li><li><a class="nounderline abstract_t">Friedman DR, Weinberg JB, Barry WT, et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res 2009; 15:6947.</a></li><li><a class="nounderline abstract_t">Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101.</a></li><li><a class="nounderline abstract_t">Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208:1389.</a></li><li><a class="nounderline abstract_t">Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119:329.</a></li><li><a class="nounderline abstract_t">Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119:521.</a></li><li><a class="nounderline abstract_t">Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121:468.</a></li><li><a class="nounderline abstract_t">Lionetti M, Fabris S, Cutrona G, et al. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol 2014; 165:629.</a></li><li><a class="nounderline abstract_t">Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526:519.</a></li><li><a class="nounderline abstract_t">International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17:779.</a></li><li><a class="nounderline abstract_t">Woyach JA, Ghia P, Byrd JC, et al. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clin Cancer Res 2023; 29:3065.</a></li><li><a class="nounderline abstract_t">Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370:2286.</a></li><li><a class="nounderline abstract_t">Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014; 370:2352.</a></li><li><a class="nounderline abstract_t">Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol 2015; 1:80.</a></li><li><a class="nounderline abstract_t">Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 2017; 35:1437.</a></li><li><a class="nounderline abstract_t">Black GS, Huang X, Qiao Y, et al. Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. Blood 2022; 140:401.</a></li><li><a class="nounderline abstract_t">Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 2021; 397:892.</a></li><li><a class="nounderline abstract_t">Wang E, Mi X, Thompson MC, et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med 2022; 386:735.</a></li><li><a class="nounderline abstract_t">Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica 2019; 104:e434.</a></li><li><a class="nounderline abstract_t">Blombery P, Anderson MA, Gong JN, et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov 2019; 9:342.</a></li><li><a class="nounderline abstract_t">Lucas F, Larkin K, Gregory CT, et al. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. Blood 2020; 135:2192.</a></li><li><a class="nounderline abstract_t">Blombery P, Thompson ER, Nguyen T, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood 2020; 135:773.</a></li><li><a class="nounderline abstract_t">Giles FJ, O'Brien SM, Keating MJ. Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 1998; 25:117.</a></li><li><a class="nounderline abstract_t">Kjeldsberg CR, Marty J. Prolymphocytic transformation of chronic lymphocytic leukemia. Cancer 1981; 48:2447.</a></li><li><a class="nounderline abstract_t">Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation. Br J Haematol 1986; 64:77.</a></li><li><a class="nounderline abstract_t">Kanzler H, Küppers R, Helmes S, et al. Hodgkin and Reed-Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 2000; 95:1023.</a></li><li><a class="nounderline abstract_t">Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006; 107:1294.</a></li><li><a class="nounderline abstract_t">Hoechstetter MA, Busch R, Eichhorst B, et al. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia 2020; 34:1038.</a></li><li><a class="nounderline abstract_t">Hoechstetter MA, Busch R, Eichhorst B, et al. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia 2017; 31:2833.</a></li><li><a class="nounderline abstract_t">Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 2020; 135:1859.</a></li><li><a class="nounderline abstract_t">Ahn IE, Tian X, Ipe D, et al. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J Clin Oncol 2021; 39:576.</a></li><li><a class="nounderline abstract_t">Morabito F, Tripepi G, Del Poeta G, et al. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. Am J Hematol 2021; 96:E168.</a></li><li><a class="nounderline abstract_t">Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood 2016; 128:2093.</a></li><li><a class="nounderline abstract_t">da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a population-based cohort. Blood 2016; 128:2181.</a></li><li><a class="nounderline abstract_t">Molica S, Giannarelli D, Mirabelli R, et al. Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood 2018; 131:365.</a></li><li><a class="nounderline abstract_t">Parikh SA, Rabe KG, Kay NE, et al. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood 2021; 138:149.</a></li><li><a class="nounderline abstract_t">Baumann T, Moia R, Gaidano G, et al. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia 2021; 35:2325.</a></li><li><a class="nounderline abstract_t">Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109:4679.</a></li><li><a class="nounderline abstract_t">Gentile M, Mauro FR, Rossi D, et al. Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 2014; 167:224.</a></li><li><a class="nounderline abstract_t">Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009; 27:1637.</a></li><li><a class="nounderline abstract_t">Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97:256.</a></li><li><a class="nounderline abstract_t">Moreno A, Villar ML, Cámara C, et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001; 97:242.</a></li><li><a class="nounderline abstract_t">Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol 2009; 145:801.</a></li><li><a class="nounderline abstract_t">Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006; 132:705.</a></li><li><a class="nounderline abstract_t">Grubor V, Krasnitz A, Troge JE, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009; 113:1294.</a></li><li><a class="nounderline abstract_t">Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121:1403.</a></li><li><a class="nounderline abstract_t">Garg R, Wierda W, Ferrajoli A, et al. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 2012; 118:3531.</a></li><li><a class="nounderline abstract_t">Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524.</a></li><li><a class="nounderline abstract_t">Garcìa-Marco JA, Price CM, Ellis J, et al. Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. Leukemia 1996; 10:1705.</a></li><li><a class="nounderline abstract_t">Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107:742.</a></li><li><a class="nounderline abstract_t">Thompson PA, O'Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015; 121:3612.</a></li><li><a class="nounderline abstract_t">Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 2019; 133:1205.</a></li><li><a class="nounderline abstract_t">Kittai AS, Miller C, Goldstein D, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood 2021; 138:2372.</a></li><li><a class="nounderline abstract_t">Rigolin GM, Del Giudice I, Bardi A, et al. Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Blood 2021; 138:2727.</a></li><li><a class="nounderline abstract_t">Fürstenau M, Thus YJ, Robrecht S, et al. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood 2023; 142:446.</a></li><li><a class="nounderline abstract_t">Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118:6904.</a></li><li><a class="nounderline abstract_t">Hahn CN, Scott HS. Spliceosome mutations in hematopoietic malignancies. Nat Genet 2011; 44:9.</a></li><li><a class="nounderline abstract_t">Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44:47.</a></li><li><a class="nounderline abstract_t">Mori J, Takahashi Y, Tanimoto T. SF3B1 in chronic lymphocytic leukemia. N Engl J Med 2012; 366:1057; author reply 1057.</a></li><li><a class="nounderline abstract_t">Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011; 118:2821.</a></li><li><a class="nounderline abstract_t">Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 2011; 118:6353.</a></li><li><a class="nounderline abstract_t">Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2011; 117:1492.</a></li><li><a class="nounderline abstract_t">Lipshutz MD, Mir R, Rai KR, Sawitsky A. Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia. Cancer 1980; 46:1422.</a></li><li><a class="nounderline abstract_t">Pangalis GA, Boussiotis VA, Kittas C. B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouv Rev Fr Hematol 1988; 30:373.</a></li><li><a class="nounderline abstract_t">Rozman C, Montserrat E, Rodríguez-Fernández JM, et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64:642.</a></li><li><a class="nounderline abstract_t">Rozman C, Hernandez-Nieto L, Montserrat E, Brugues R. Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia. Br J Haematol 1981; 47:529.</a></li><li><a class="nounderline abstract_t">Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113:5237.</a></li><li><a class="nounderline abstract_t">Visone R, Rassenti LZ, Veronese A, et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114:3872.</a></li><li><a class="nounderline abstract_t">Cui B, Chen L, Zhang S, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 2014; 124:546.</a></li><li><a class="nounderline abstract_t">Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014; 32:897.</a></li><li><a class="nounderline abstract_t">Brachtl G, Piñón Hofbauer J, Greil R, Hartmann TN. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol 2014; 93:361.</a></li><li><a class="nounderline abstract_t">Zucchetto A, Caldana C, Benedetti D, et al. CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood 2013; 122:3317.</a></li><li><a class="nounderline abstract_t">Majid A, Lin TT, Best G, et al. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 2011; 35:750.</a></li><li><a class="nounderline abstract_t">Walsby E, Buggins A, Devereux S, et al. Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. Blood 2014; 123:3607.</a></li><li><a class="nounderline abstract_t">Molica S, Vitelli G, Levato D, et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107:605.</a></li><li><a class="nounderline abstract_t">Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96:3181.</a></li></ol></div><div id="topicVersionRevision">Topic 4489 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1139039" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical staging of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7237385" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841436" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Spontaneous clinical regression in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3347094" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797299" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18373706" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736453" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736453" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/890666" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A clinical staging system for chronic lymphocytic leukemia: prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984187" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392104" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Biomarker: Predictive or Prognostic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33326253" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32206772" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136261" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genomic aberrations and survival in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316624" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7888675" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8241511" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052620" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7949187" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596683" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11180073" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150006" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167526" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35614318" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477712" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477713" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411418" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943357" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492934" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24652989" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788964" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411304" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12149225" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11877310" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18053068" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050308" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26276669" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26841802" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577710" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393534" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24868078" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15813847" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3677006" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954968" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26466571" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mutations driving CLL and their evolution in progression and relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9116297" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440242" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843217" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : ATM associates with and phosphorylates p53: mapping the region of interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523469" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198729" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459216" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686453" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867199" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15746080" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15802535" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251535" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344317" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418492" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16621959" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840733" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825496" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675331" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical significance of CD38 expression in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861443" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642962" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670202" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086416" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : NOTCH1 mutations in CLL associated with trisomy 12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077063" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23086750" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24579978" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26200345" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Non-coding recurrent mutations in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27185642" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37314786" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869598" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869597" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ibrutinib resistance in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26182309" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418267" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35476648" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676628" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35196427" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31004028" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30514704" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32232486" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31951646" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9482533" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Chronic lymphocytic leukemia in (Richter's) transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7296493" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Prolymphocytic transformation of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3463362" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of 'prolymphocytoid' transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648418" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hodgkin and Reed-Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16902984" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32042081" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28804126" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32267500" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33026937" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33580969" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27549308" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27605511" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The CLL-IPI applied in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29084773" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33876228" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33542480" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299097" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041609" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224852" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133769" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133767" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19388937" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487171" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922857" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243274" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22139735" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12434020" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892671" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179374" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26193999" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30602617" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34314481" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34587233" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37172204" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039264" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22200771" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Spliceosome mutations in hematopoietic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22158541" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417262" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : SF3B1 in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765023" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998207" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048153" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7417943" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3222147" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6466871" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7213576" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144983" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717645" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Karyotype-specific microRNA signature in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24914134" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24516016" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24288111" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24068493" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093051" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24637360" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583266" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050001" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
